Adaptimmune licenses Universal's gene editing tech

Universal Cells Inc. (Seattle, Wash.) granted Adaptimmune Therapeutics plc (NASDAQ:ADAP) an exclusive, worldwide license to use Universal Cells' gene editing technology to develop and manufacture allogeneic T cell immunotherapies.

Universal Cells will receive $5.5 million up front and is eligible for $41 million in milestones, plus a profit-share payment for the first product that emerges from the collaboration and royalties on sales of additional products. ...